Considering the immune tolerance of the liver, the combination of CTLA-4 and PD-1 blockers is expected to have a synergistic effect to achieve better outcomes in patients with NSCLC liver metastasis. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.